SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience (NASDAQ:PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported product revenues for the fiscal second quarter ended January 31, 2011 of $58,400, compared with product revenues of $327,000 in the same quarter of the prior fiscal year. The Company reported a net loss of $2,479,600 or $(0.07) per share for the current quarter, compared with a net loss of $1,766,200 or $(0.05) per share in the second fiscal quarter last year. Also during the second quarter of fiscal year 2011, the Company recorded licensing revenue of $10,000.
